company background image
RMD logo

ResMed NYSE:RMD Lagerbericht

Letzter Preis

US$227.75

Marktkapitalisierung

US$33.4b

7D

5.2%

1Y

37.5%

Aktualisiert

16 Aug, 2024

Daten

Finanzdaten des Unternehmens +

RMD Aktienübersicht

ResMed Inc. entwickelt, produziert, vertreibt und vermarktet medizinische Geräte und cloudbasierte Softwareanwendungen für den Gesundheitsmarkt.

RMD grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung5/6
Künftiges Wachstum2/6
Vergangene Leistung5/6
Finanzielle Gesundheit6/6
Dividenden4/6

Community Narratives

Narratives bring a range of perspectives from our community.

US$232.83
FV
2.2% undervalued intrinsic discount
6.94%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
9 days agoauthor updated this narrative

ResMed Inc. Wettbewerber

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für ResMed
Historische Aktienkurse
Aktueller AktienkursUS$227.75
52-Wochen-HochUS$228.02
52-Wochen-TiefUS$132.24
Beta0.66
11 Monat Veränderung10.59%
3 Monate Veränderung4.20%
1 Jahr Veränderung37.47%
33 Jahre Veränderung-20.28%
5 Jahre Veränderung72.30%
Veränderung seit IPO33,797.67%

Aktuelle Nachrichten und Updates

ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Aug 05
ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Recent updates

ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Aug 05
ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?

Jul 29
Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?

Returns On Capital Are A Standout For ResMed (NYSE:RMD)

Jul 15
Returns On Capital Are A Standout For ResMed (NYSE:RMD)

ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating

Jul 03

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

Jul 02
An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Apr 30
ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Apr 30
Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

Apr 18
ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Mar 22
With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

Mar 10
Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Feb 12
An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Why ResMed Is One Of My Top Picks In 2024

Jan 22

A First Look At ResMed

Jan 09

ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Dec 20
ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Dec 06
Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Nov 10
Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

Nov 01
Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

ResMed: Weight-Loss Drug Worries Provide Buying Opportunity

Oct 28

ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity

Sep 12

ResMed Has Become A Steal (Rating Upgrade)

Aug 10

ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

Aug 07
ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Jul 30
ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Jul 16
Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Compound Your Wealth With ResMed

Jul 04

A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

Jul 02
A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

May 26
We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital

Apr 24
ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital

Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors

Apr 09
Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors

A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

Mar 26
A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

ResMed goes ex dividend tomorrow

Feb 07

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Feb 06
ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Aktionärsrenditen

RMDUS Medical EquipmentUS Markt
7D5.2%2.7%3.9%
1Y37.5%10.5%25.3%

Rendite im Vergleich zur Industrie: RMD übertraf die Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von 1.5 erzielte.

Rendite vs. Markt: RMD übertraf den Markt US, der im vergangenen Jahr eine Rendite von 12.4 erzielte.

Preisvolatilität

Is RMD's price volatile compared to industry and market?
RMD volatility
RMD Average Weekly Movement5.5%
Medical Equipment Industry Average Movement8.4%
Market Average Movement6.3%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market3.2%

Stabiler Aktienkurs: RMD hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: RMDDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
19899,980Mick Farrellwww.resmed.com

ResMed Inc. entwickelt, produziert, vertreibt und vermarktet medizinische Geräte und cloudbasierte Softwareanwendungen für den Gesundheitsmarkt. Das Unternehmen ist in zwei Segmenten tätig: Sleep and Respiratory Care und Software as a Service. Es bietet verschiedene Produkte und Lösungen für eine Reihe von Atmungsstörungen an, darunter ApneaLink Air, ein tragbares Diagnosegerät, das Oximetrie, Atemanstrengung, Puls, Nasenfluss und Schnarchen misst, und NightOwl, ein tragbares, mit der Cloud verbundenes Einweg-Diagnosegerät, das den AHI auf der Grundlage des abgeleiteten peripheren arteriellen Tonus, der Aktigraphie und der Oximetrie über mehrere Nächte misst.

ResMed Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von ResMed im Vergleich zum Marktanteil des Unternehmens?
RMD grundlegende Statistiken
MarktanteilUS$33.39b
Gewinn(TTM)US$1.02b
Umsatz(TTM)US$4.69b

32.8x

Kurs-Gewinn-Verhältnis

7.1x

Kurs-Umsatz-Verhältnis

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
RMD Gewinn- und Verlustrechnung (TTM)
EinnahmenUS$4.69b
Kosten der EinnahmenUS$2.00b
BruttogewinnUS$2.69b
Sonstige AusgabenUS$1.67b
UmsatzUS$1.02b

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)6.95
Bruttomarge57.38%
Nettogewinnspanne21.79%
Schulden/Eigenkapital-Verhältnis14.5%

Wie hat sich RMD auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

0.9%

Aktuelle Dividendenrendite

28%

Ausschüttungsquote